pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Data Readout · news · pharmadog
← back to Data Readout
News · Data Readout
45
stories
6h
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
1d
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
2d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
Enveda’s exercise-simulating obesity tablet clears early clinical test
biospace
3d
Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss
fiercebiotech
4d
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
4d
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
7d
Skye and Redx form new entity with $125M to advance fibrosis assets
fiercebiotech
7d
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
10d
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
fiercebiotech
11d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
11d
aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drug
fiercebiotech
14d
Replimune to ride wave of physician support to launch advanced melanoma therapy
biospace
15d
BioVie shares halve on murky Parkinson’s disease readout
biospace
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
17d
Vertex unfazed by competitive IgAN space as FDA verdict looms
biospace
17d
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
22d
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
biospace
24d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
24d
Boston Scientific unveils major restructuring, plots job cuts amid savings drive
fiercebiotech
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
28d
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 22, 26
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
biospace
Jul 22, 26
Celldex scraps antibody in prurigo nodularis after Phase 2 flop
endpoints
Jul 21, 26
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
biospace
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 17, 26
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
biospace
Jul 16, 26
Veradermics keeps ‘momentum going’ as baldness drug helps women with hair loss
biopharma dive
← prev
page 1 of 2
next →
